MARY CROWLEY NEWSLETTER: VOLUME 11, ISSUE 3
PHASE I OPEN-LABEL STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF DILPACIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
PHASE I STUDY OF 2- OR 3-WEEK DOSING OF TELISOTUZUMAB VEDOTIN, AN ANTIBODY–DRUG CONJUGATE TARGETING C-MET, MONOTHERAPY IN PATIENTS WITH ADVANCED NON–SMALL CELL LUNG CARCINOMA
A PHASE 1B STUDY OF TELISOTUZUMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH NSCLC
Telisotuzumab vedotin (Teliso-V) is an antic-Met–directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC…
CASE REPORT: MARKED SURVIVAL ADVANTAGE OF TWO COLORECTAL CANCER PATIENTS WITH LIVER METASTASES TREATED WITH VIGIL AND FOLFOX-6
Colorectal cancer is the third most diagnosed cancer in the United States. Five-year survival rates remain low and many patients will develop liver metastasis….
A PHASE 1B STUDY OF TELISOTUZUMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH NSCLC
Telisotuzumab vedotin (Teliso-V) is an antic-Met–directed antibody-drug conjugate that has exhibited antitumor activity as monotherapy in NSCLC. Its potential activity combined with programmed cell death protein-1 inhibitors has not been previously evaluated.
MAXIMUM TOLERATED DOSE AND ANTI-TUMOR ACTIVITY OF INTRAPERITONEAL CANTRIXIL (TRX-E-002-1)
Cantrixil is a novel third-generation benzopyran molecule, with potent cytotoxicity against chemoresistant ovarian cancer stem cells and chemosensitive ovarian cancer cell lines. The aims of this Phase I study were to define the…
PIRTOBRUTINIB IN RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (BRUIN): A PHASE 1/2 STUDY
Covalent Bruton’s tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance…